Carl Zeiss Meditec AG

Chen Jining Meets Leaders of Boehringer Ingelheim and ZEISS, Introduces Shanghai's Development Plans for Biomedicine and Optical and Optoelectronic Equipment Manufacturing Industries

Carl Zeiss Meditec Receives NMPA Approval for ARTEVO 750 and ARTEVO 850 Ophthalmic Microscopes

Goldman Sachs analyst Richard Felton has maintained a Hold rating on Carl Zeiss Meditec (0DHC) with a price target of €28.00. Felton, a 3-star analyst, has an average return of 2.7% and a 52.34% success rate. Additionally, Deutsche Bank's Falko Friedrichs also issued a Hold rating, while J.P. Morgan maintained a Sell rating on the same day.

Tip Ranks

Goldman Sachs

Deutsche Bank AG

JPMorgan Chase

GS Hldg R

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Carl Zeiss Meditec (0DHC) Gets a Hold from Goldman Sachs

Sidra Medicine in Qatar has been designated as a ZEISS labs@location Reference Customer through its Advanced Imaging Core (AIC). This recognition places Sidra among a select group of international research hospitals and academic centers known for excellence in advanced microscopy and imaging technologies. The designation enhances Sidra's ability to support researchers and clinicians, strengthens its competitiveness for grants, and reinforces its position as a regional hub for precision medicine and scientific collaboration.

Zawya

ZAWYA: Sidra Medicine advanced Imaging Core recognized as ZEISS labs@location Reference Customer

.SPX

.NDX

U.S. stocks are expected to show mixed performance in early trading on Wednesday, following a weak previous session. Major index futures indicate a mixed open, with Nasdaq futures up 0.3%, while S&P 500 futures are down 0.1% and Dow futures down 0.5%. The Nasdaq may see gains due to strength in tech stocks, particularly Nvidia (NVDA).

- Stocks are projected to open mixed on Wednesday, following weakness in the previous session.  
- Nasdaq futures are up by 0.3 percent, while S&P 500 and Dow futures are down by 0.1 percent and 0.5 percent, respectively.  
- The Nasdaq's potential strength is attributed to positive movements among technology stocks, such as Nvidia (NVDA).

rttnews

S&P 500

NASDAQ-100

Spdr Select Tech

ProShares Ultra QQQ

SPDR S&P 500

YieldMax NVDA Option Income Strategy ETF

GraniteShares 2x Long NVDA Daily ETF

Fidelity Nasdaq Composite Index ETF

Invesco Nasdaq 100 ETF

Pacer Cash COWZ 100-Nasdaq100RotatorETF

Proshares UltraPro QQQ

T-Rex 2X Long NVIDIA Daily Target ETF

Invesco QQQ Trust

NASDAQ Composite Index

Dow Jones Industrial Average

NVIDIA

NVIDIA Corporation

U.S. Stocks May Turn In Mixed Performance In Early Trading

J.P. Morgan analyst David Adlington maintained a Sell rating on Carl Zeiss Meditec today and set a price target of €21.70.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks According to TipRanks, Adlington is ranked #11858 out of 12188 analysts. Currently, the analyst consensus on Carl Zeiss Meditec is a Hold with an average price target of €28.28.

Carl Zeiss Meditec (0DHC) Gets a Sell from J.P. Morgan

RBC Capital's Charles Weston has maintained a Hold rating on Carl Zeiss Meditec (0DHC) with a price target of €32.00. Barclays also holds a Hold rating with a price target of €30.00. Weston focuses on the Healthcare sector and has an average return of -6.9% with a 33.20% success rate on his stock recommendations.

ROYAL BANK OF CANADA

Oxford BioMedica plc

Barclays

RBC Capital Keeps Their Hold Rating on Carl Zeiss Meditec (0DHC)

Global optics leader ZEISS is significantly investing in India, driven by the country's youthful population and increasing demand for quality vision products. India ranks among ZEISS's top three fastest-growing markets, alongside China and Southeast Asia. The company reports a revenue of Rs 2,410 crore for the financial year ending March 31, 2025, with a growth rate of 17%. ZEISS plans to open a new lens manufacturing facility in Karnataka, which will be the largest of its kind globally, catering not only to India but also to markets in the Middle East, Africa, and Europe.

Business Standard

ZEISS bets big on India as youth boost demand for vision products

The Supervisory Board of Leica Camera AG has appointed Andreas Voll as the new CEO, effective April 1, 2026, succeeding Matthias Harsch. Voll, with extensive experience in premium technology and brand management, aims to enhance innovation and growth while preserving Leica's unique brand identity. His strategic priorities include expanding digital imaging solutions, developing the premium product portfolio, and strengthening global sales. Until Voll's start date, Harsch will continue to manage operations and assist in the transition.

prnewswire

08:52 ETAndreas Voll Appointed Chief Executive Officer of Leica Camera AG Effective April 1, 2026

UBS analyst Graham Doyle has maintained a Hold rating on Carl Zeiss Meditec (0DHC) with a price target of €25.00. Doyle, who has an average return of -1.4% and a 51.88% success rate, focuses on the Healthcare sector. The analyst consensus for Carl Zeiss Meditec is also a Hold, with a higher price target consensus of €31.10.

UBS Sticks to Its Hold Rating for Carl Zeiss Meditec (0DHC)

ZEISS Vision Care has formed a strategic partnership with Medical Eyeglass Center (MEC) to enhance optical care and patient experience. This multi-year agreement designates MEC as the exclusive optical dispensary management organization for ZEISS, providing access to advanced lens innovations and operational support. The collaboration aims to integrate optical dispensaries into clinical care, improving patient satisfaction and driving growth for independent eye care practices. Both companies emphasize a commitment to clinical excellence and operational efficiency, setting a new standard in optical care delivery.

fidelity

ZEISS Vision Care and Medical Eyeglass Center Form Strategic Partnership, Combining Optical Excellence with Patient-Centric Operational Systems

Carl Zeiss Meditec AG(AFX.DE)

Carl Zeiss Meditec (0DHC) Gets a Hold from Goldman Sachs

ZAWYA: Sidra Medicine advanced Imaging Core recognized as ZEISS labs@location Reference Customer

U.S. Stocks May Turn In Mixed Performance In Early Trading

Carl Zeiss Meditec (0DHC) Gets a Sell from J.P. Morgan

RBC Capital Keeps Their Hold Rating on Carl Zeiss Meditec (0DHC)